Localization of"physician-pharmacist co-management"in chronic respiratory diseases:concepts,im-plementation pathways,and preliminary outcomes
10.3969/j.issn.1671-332X.2025.11.002
- VernacularTitle:呼吸系统慢性疾病中慢阻肺医药共管的本土化探索:理念、实施路径与初步成效
- Author:
Yingying XIAO
1
;
Bingqin WEN
1
;
Xiao MENG
1
;
Zhipeng WANG
1
;
Huiyin XU
1
;
Yongbang CHEN
1
;
Zixuan LIU
1
;
Pengjiu YU
1
;
Rongchang CHEN
1
;
Liang PENG
1
;
Li WEI
1
Author Information
1. 广州医科大学附属第一医院 广东 广州 510160
- Publication Type:Journal Article
- Keywords:
Physician-pharmacist co-management;
COPD management;
Collaborative drug therapy management;
Cost-effectiveness of health insurance;
Healthcare reform
- From:
Modern Hospital
2025;25(11):1644-1647
- CountryChina
- Language:Chinese
-
Abstract:
With the rising prevalence of chronic diseases and an aging population,China's traditional segmented health-care delivery model is increasingly inadequate for meeting the growing demand for long-term,systematic health management.In response,the"Physician-Pharmacist Co-management"model has emerged,aiming to enhance the quality and continuity of care through close collaboration between physicians and pharmacists.This paper starts from the concept and origin of"Physician-Phar-macist Co-management"model,focusing on its China-specific advantages shaped by national healthcare policies and clinical real-ities.Unlike the internationally recognized Collaborative Drug Therapy Management(CDTM)model,the Chinese approach re-flects local healthcare structures and needs.Using obstructive pulmonary disease(COPD)as a case study,we examine the mod-el's application and value in managing chronic respiratory diseases.Data indicate that,after the implementation of"physician-pharmacist co-management"model in COPD patients,the CAT score decreased by approximately 24％,the annual rate of acute exacerbation-related hospitalizations declined by about 72％,and the proportion of patients with regular pulmonary rehabilitation exercise habits increased by roughly 3.3-fold.Additionally,the percentage of patients without adverse reactions rose from 47.37％to 64.41％,and the vaccination rate increased by about 2.7-fold.These findings demonstrate the model's significant advantages in improving clinical outcomes,enhancing patient adherence,and reducing healthcare costs.Despite benefits,howev-er,the"Physician-Pharmacist Co-management"model in China faces several challenges,including limited public awareness,gaps in pharmacist training,and insufficient policy support.To address these challenges,this study recommends strengthening public education,establishing comprehensive evaluation systems for pharmaceutical professionals,and improving incentive mech-anisms.Overall,the findings suggest that the"Physician-Pharmacist Co-management"model holds considerable promise for im-proving the quality of chronic disease management,enhancing patient adherence,and optimizing healthcare resource utilization in China.
